Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 13/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 13/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1380405 | 0.89 | GRM5 (0.57) | GCKKCNH2 | |
| SCHEMBL13547407 | 0.86 | GCK (0.64) | GCKKCNH2P2RX3P2RX2 | |
| SCHEMBL1376997 | 0.86 | GCK (0.64) | GCKKCNH2P2RX3P2RX2 | |
| SCHEMBL1378863 | 0.84 | GCK (0.58) | GCKKCNH2 | |
| SCHEMBL1427020 | 0.84 | GCK (0.51) | GCKKCNH2P2RX3P2RX2 | |
| SCHEMBL1380582 | 0.84 | GCK (0.52) | GCKKCNH2P2RX3P2RX2 | |
| SCHEMBL12510380 | 0.84 | GCK (0.51) | GCKKCNH2P2RX3P2RX2 | |
| SCHEMBL1378895 | 0.83 | GCK (0.55) | GCKKCNH2 | |
| SCHEMBL1427043 | 0.83 | GCK (0.49) | GCKKCNH2 | |
| SCHEMBL2201529 | 0.83 | GCK (0.49) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | claimed |
| EP-2305674-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| JP-4651714-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | claimed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| EP-2305674-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2301929-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (Publ) (SE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301935-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (Publ) (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-7842694-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | GCK 1/4885KCNH2 1128/4885P2RX3 1736/4885 |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | GCK 1/4885KCNH2 993/4885P2RX3 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.